Cancer Treatment

Product Details:

:

Palbociclib is a targeted anticancer medication, specifically a selective and reversible inhibitor of cyclin-dependent kinases CDK4 and CDK6. It is prescribed for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, administered orally in 125 mg dosage.

By inhibiting CDK4/6, Palbociclib blocks cancer cell progression from the G1 into the S phase of the cell cycle, effectively halting cell division. When combined with hormonal therapies (e.g., aromatase inhibitors or fulvestrant), it enhances tumor growth control.

• Approved by FDA (2015) and EMA (2016) for combination therapy in HR+/HER2– metastatic or locally advanced breast cancer  

• Used:

   

  • Upfront combination with aromatase inhibitors (letrozole, anastrozole, exemestane)

  • Post-endocrine progression with fulvestrant  

  • Dosage & Administration

     

    Parameter

    Details

    125 mg dose form

    Tablets (also available in 100 mg & 75 mg) Regimen 21 consecutive days on, 7 days off — repeated in 28‑day cycles Administer orally with or without food, at consistent times; swallow whole   Hepatic/Renal No dose change for mild/moderate impairment. For Child‑Pugh C liver cases, reduce to 75 mg Monitoring CBC before each cycle, mid‑cycle (Day 15 of Cycles 1 & 2), with ongoing clinical checks      Clinical Benefits PALOMA‑2 trial: 125 mg Palbociclib + letrozole improved progression-free survival to ~24.8 months vs 14.5 months.   PALOMA‑3 trial: significant PFS improvement and enhanced response rates with Palbociclib + fulvestrant

    .
  • Safety & Side Effects

    • Common: neutropenia (> grade 3), leukopenia, anemia, fatigue, nausea, diarrhea, infections

Product Details:

Tofamark 5 mg (Tofacitinib) – Product Description Active Ingredient

Each tablet contains Tofacitinib 5 mg, a potent Janus kinase (JAK) inhibitor.

Indications
Tofamark is indicated for adults in the management of:
 

Moderate to severe rheumatoid arthritis

Psoriatic arthritis

Ulcerative colitis

Ankylosing spondylitis

Mode of Action
It works by selectively inhibiting JAK enzymes, reducing pro‑inflammatory cytokine activity, thus alleviating pain, swelling, and preventing joint and tissue damage.
Dosage & Administration

Adults: Typically 5 mg twice daily (or once daily extended-release) depending on the condition and combination therapy.

Administration: Can be taken with or without food. Swallow whole. Maintain consistent dosing schedule.

Key Benefits
 

Reduces inflammation, tenderness, and joint stiffness

Improves physical function and quality of life

Slows disease progression and structural damage

Side Effects & Precautions
 
Common: headache, upper respiratory infection, diarrhea, nasopharyngitis
Serious (seek immediate care): blood clots, GI perforation, opportunistic infections (e.g., TB, fungal, herpes zoster)

Important Safety Notes:
 

Screen for TB, hepatitis B/C, and latent infections before starting

Avoid in active infections

Regular lab monitoring (CBC, liver, kidney, lipids) advised

Not recommended during pregnancy or breastfeeding unless benefits justify risks

Packaging & Storage
 

Format: 5 mg tablets, pack sizes vary (e.g., 1 × 10 strips or 60‑tablet bottles)

Storage: Below 30 °C, protect from moisture and sunlight

Target Audience

Rheumatologists, gastroenterologists, and specialty clinics

Patients with inadequate response or intolerance to conventional DMARDs or biologics

Manufacturer / Supplier Details
 

Available through Aprazer (manufacturer of Tofamark) and Cipla (Tofajak)

Export-ready: MOQ 1 box, competitive pricing (₹2,200–₹2,500 per box)

✅ Why List Tofamark 5 mg on IndiaMART?

Clinically proven JAK‑inhibitor trusted in autoimmune and inflammatory disorders

Attractive margins: cost-effective generics vs. branded options

Global demand: key markets across India, Middle East, Africa, Europe.